Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 10/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27736502 | 1.00 | GSR (0.43) | GSRCA2ALDH1A1MAPTMEN1 | |
| SCHEMBL14499695 | 1.00 | GSR (0.43) | GSRCA2ALDH1A1MAPTMEN1 | |
| SCHEMBL14499700 | 0.85 | GSR (0.36) | GSRCA2ALDH1A1 | |
| SCHEMBL12456826 | 0.85 | GSR (0.36) | GSRCA2ALDH1A1 | |
| SCHEMBL12456808 | 0.85 | GSR (0.36) | GSRCA2ALDH1A1 | |
| SCHEMBL14499691 | 0.83 | GSR (0.44) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL14499680 | 0.83 | GSR (0.44) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL12456825 | 0.81 | GSR (0.37) | GSRCA2ALDH1A1 | |
| SCHEMBL12456812 | 0.78 | GSR (0.36) | GSRCA2ALDH1A1 | |
| SCHEMBL12456809 | 0.78 | GSR (0.36) | GSRCA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135380-A1 | O-nitro compounds, pharmaceutical compositions thereof and uses thereof | RADIORX, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135380-A1 | O-nitro compounds, pharmaceutical compositions thereof and uses thereof | NOS1, NOS2, NOS3 | GSR 262/4885CA2 1885/4885ALDH1A1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.